New drug combo aims to free MDS patients from frequent blood transfusions
NCT ID NCT07096297
Summary
This study is testing whether combining two drugs, luspatercept and darbepoetin alfa, can help patients with a specific, lower-risk form of myelodysplastic syndrome (MDS) who need regular blood transfusions. The main goal is to see if the treatment can help patients go longer periods without needing a transfusion and improve their red blood cell counts. The trial will enroll about 60 adults who have not responded to other standard treatments for their anemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS (MYELODYSPLASTIC SYNDROME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harold C. Simmons Comprehensive Cancer Center of UT Southwestern
NOT_YET_RECRUITINGDallas, Texas, 75235, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.